Dr. Dava Newman of MIT says setting big goals will encourage more participation from people of diverse backgrounds and skillsets.
Dr. Dava Newman of MIT says setting big goals will encourage more participation from people of diverse backgrounds and skillsets.
The U.S. government has asked Australia to scrap proposed laws that will make it the first country in the world to force Facebook Inc and Alphabet Inc's Google to pay for news sourced from local media outlets. In a submission asking the government to "suspend" the plans, assistant U.S. trade representatives Daniel Bahar and Karl Ehlers, suggested Australia instead "further study the markets, and if appropriate, develop a voluntary code." Under the law, which has broad political support and is currently before a senate committee, Google and Facebook will be subject to mandatory price arbitration if a commercial agreement on payments to Australian media cannot be reached.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kandi Technologies Group, Inc. (NASDAQ: KNDI) between March 15, 2019 and November 27, 2020, inclusive (the "Class Period"), of the important February 9, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Kandi investors under the federal securities laws.
The Field Service Management Software Market will grow by USD 3.43 bn during 2020-2024
Magny is a nightmare matchup for most UFC welterweights.
NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Decision Diagnostics Corp. (OTC: DECN) between March 3, 2020 and December 17, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Decision Diagnostics investors under the federal securities laws. To join the Decision Diagnostics class action, go to http://www.rosenlegal.com/cases-register-2009.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Decision Diagnostics had not developed any viable COVID-19 test, much less a test that could detect COVID-19 in less than one minute; (2) Decision Diagnostics could not meet the U.S. Food and Drug Administration’s emergency use authorization testing requirements for its purported COVID-19 test; (3) accordingly, defendants had misrepresented the timeline within which Decision Diagnostics could realistically bring its COVID-19 test to market; (4) all of the foregoing subjected defendants to an increased risk of regulatory oversight and enforcement; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-2009.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 firstname.lastname@example.org email@example.com firstname.lastname@example.org www.rosenlegal.com
The three-bedroom house has received hundreds of enquiries – but it’s unlivable.
Slate Office REIT (TSX: SOT.UN) (the "REIT"), an owner and operator of North American office real estate, announced today that the Board of Trustees has declared a distribution for the month of January 2021 of C$0.0333 per trust unit of the REIT, representing $0.40 per unit of the REIT on an annualized basis.
Mikel Arteta hailed Pierre-Emerick Aubameyang’s mental strength after the Arsenal captain bounced back to score twice against Newcastle. Aubameyang has endued a difficult season so far and before a 3-0 win over Newcastle, he had only scored six times in the current campaign. Aubameyang, however, bounced back from that and scored twice as the Gunners ran out 3-0 winners to make it six games without defeat in all competitions.
Mitchell Starc has declared himself fit to bowl on the final day of the Gabba Test as Australia chase 10 wickets to secure a series win against a defiant India.
Sources claim the First Lady and Ivanka are locked in a cold war and there's one major sign that they're correct.
There will be no workouts in Indianapolis, a key part of the NFL's offseason.
Recently evicted star Jack Vidgen spilled some juicy camp secrets.
A comfortable jacket never goes out of style.
Tourism and Transport Forum chief executive Margy Osmond is urging the federal government to provide more support once JobKeeper subsidies end in March.
Following an increasing number of reports in early January, Telegram says it took decisive action against US channels that advocated violence.
CALGARY, Alberta, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Freehold Royalties Ltd. (“Freehold”) (TSX:FRU) is pleased to announce that it has appointed David Spyker as its new President and Chief Executive Officer. Mr. Spyker joined Freehold as Vice-President, Production in November 2016 and was appointed Chief Operating Officer in March 2019. Since September 2020 Mr. Spyker has served as Freehold's Interim President and Chief Executive Officer. Mr. Spyker has over 30 years of industry experience. He holds a Bachelor of Sciences degree in Mechanical Engineering from the University of Alberta and is a member of the Association of Professional Engineers and Geoscientists of Alberta (APEGA). Mr. Spyker's appointment is the result of a formal process to identify a permanent Chief Executive Officer that has been ongoing since September 2020. Marvin Romanow, Chair of Freehold's Board of Directors, said, "We are pleased to have Mr. Spyker continue to provide his strong leadership and strategic direction to Freehold. Although a number of excellent candidates were considered as part of the formal process to identify a new CEO, the Board believes that Mr. Spyker is the best person to lead the Freehold team into the future." Concurrent with his appointment as President and Chief Executive Officer, Mr. Spyker has also been appointed as a director of Freehold. Freehold’s focus is on acquiring and managing oil and gas royalties. Freehold’s common shares trade on the Toronto Stock Exchange in Canada under the symbol FRU. For further information, contact:Freehold Royalties Ltd.Matt DonohueManager, Investor Relations & Capital Marketst. 403.221.0833f. 403.221.0888tf. 1.888.257.1873e. email@example.com. www.freeholdroyalties.com
The global ethanol market size is expected to be worth around USD 155.6 billion by 2030 from USD 93.7 billion in 2020, growing at a CAGR of 5.2% from 2021 to 2030. Increasing usage of ethyl alcohol as biofuel is major factor driving growth of the ethanol market.OTTAWA, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Precedence Research, Recently Published Report on “Ethanol Market (By Source: Second Generation, Grain-based, and Sugar & Molasses Based; By Purity: Denatured and Undenatured; By Application: Industrial Solvents, Fuel & Fuel Additives, Beverages, Disinfectant, Personal Care, and Others) - Global Market Size, Share, Trends Analysis, Segment Forecasts, Regional Outlook 2021 - 2030”. Ethanol is a flammable chemical which is also known as ethyl alcohol. It is a renewable and colorless chemical which is primarily manufactured by the fermentation of sugar-based materials, starch, as well as cellulose based feedstocks including corn, barley, wood, and wheat, among others. Ethyl alcohol is an organic solvent having high solubility, owing to which it is mainly used in the various end-use applications in industrial sector. Ethanol is a primary component in the production of alcoholic beverages and it is extensively used in the pharmaceutical industries as a preservative. Major applications of the ethanol include fuel & fuel additives, disinfectant, beverages, personal care, industrial solvents, and others. Further, the sudden rise of the COVID-19 pandemic has led to an increased usage of alcohol-based hand sanitizers due to which demand for ethanol has been augmented tremendously. Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1188 Growth Factors: Increasing usage of ethyl alcohol as biofuel is a major factor driving growth of the global ethanol market. Additionally, increasing consumption of alcoholic beverages is among the major factors boosting demand for ethanol worldwide. Currently, due to the rise of the COVID-19 pandemic, usage of alcohol-based hand sanitizers has been increased, which is expected to boost growth of the target market in the near future. Food and Drugs Administration has approved ethanol as active ingredient in the manufacturing of alcohol based hand sanitizers, hence leading players operating on the global ethanol market are focusing on the capacity expansion and production of the ethanol. These factors are supporting in flourishing the target industry. Moreover, government in the developed as well as emerging economies are promoting ethanol production, as ethanol is a renewable biofuel. Also, growing awareness among individuals regarding environmental safety is another factor to boost growth of the target industry in the near future. Ethanol is environmental fuel thereby reduces the level of pollution which is a crucial factor for the adoption of ethanol in most of the fuel blends which is fueling growth of the target industry during the forecast period. Nevertheless, emerging markets of ethanol is anticipated to create potential opportunities for the growth of the target market. Report Highlights: Among the source segment, grain-based chemicals segment dominated the overall market in 2020, owing to enormous consumption of grain-based ethanol in several end use industries including automotive and food. The sugar & molasses-based source segment is expected to grow at a significant CAGR during the forecast time-frame.Among the purity, denatured segment accounted for the significant share. Undenatured segment is expected to grow at a significant CAGR during the forecast time-frame.Among the application, fuel & fuel additives segment accounted for the significant share. Beverages segment is expected to grow at a significant CAGR during the forecast time-frame.HPCL Biofuels Limited accounted for a significant share of the global ethanol market. Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1188 Regional Analysis: The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the global market with a market share of more than 30%, in 2020. The growth of the region primarily attributed to growing industrialization, coupled with increasing consumption of the biofuel in North America especially in the United States. As per the data published by the Renewable Fuels Association, U. S. is the major exporter of ethanol. Further, presence of leading players, along with favorable government regulations for the biofuel usage are among major factors augmenting growth of the target market in the near future. Also, growing usage of the alcohol-based hand sanitizers due to increased numbers of COVID-19 cases in North American countries is projected to fuel target market growth in the next few years. Asia Pacific is expected to register significant market share over the forecasted period owing to increasing adoption of ecofriendly fuel in the countries especially in China, India, Japan, Thailand and in the region. Also, favorable government regulations for renewable products in order to reduce environmental pollution are responsible for the high demand for ethanol in the region. Moreover, growing research and development activities by the key companies in the country is other important factors to contribute to the high market share of the Asia Pacific over the forecast period. Growth in Latin America is accredited to plentiful availability of the raw material used in ethanol production along with growing product demand from the automotive industry. African and Middle Eastern regions will display noticeable growth over the forecast period. Key Market Players and Strategies: The major companies functioning in the worldwide ethanol include Flint Hill Resources LP, Braskem, Andersons Ethanol Group, Archer Daniels Midland Company, Cargill Corporation, Aventine Renewable Energy, HPCL Biofuels Limited, Butamax Advanced Biofuels LLC, Advanced Bioenergy LLC, British Petroleum among others. Noteworthy investment in the research and development of the ethanol coupled with acquisition, mergers, and strategic collaborations are the key business strategies undertaken by the companies operating in the global ethanol market. Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1188 You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org | +1 774 402 6168 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us: https://www.linkedin.com/company/precedence-research/ https://www.facebook.com/precedenceresearch/ https://twitter.com/Precedence_R
LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover the combination of MN-166 (ibudilast) and riluzole for alleviating the negative effects of ALS, treating a patient diagnosed with ALS, and slowing progression of disease in a patient diagnosed with ALS. The allowed claims cover a wide range of doses and dosing regimens for both MN-166 (ibudilast) and riluzole. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased to receive notice that this new patent will be granted. We believe it could substantially increase the potential value of MN-166 as patients are using the combination of MN-166 and riluzole in our ongoing Phase 3 clinical trial in ALS. Previously, a similar patent was granted in the U.S., the U.S. FDA granted both orphan-drug designation and fast-track designation to MN-166 for the treatment of ALS, and the European Commission granted Orphan Medicinal Product Designation to MN-166 for the treatment of ALS." About ALS Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The nerves lose the ability to trigger specific muscles, which causes the muscles to become weak. As a result, ALS affects voluntary movement and patients in the later stages of the disease may become completely paralyzed. Life expectancy of an ALS patient is usually 2-5 years. According to the ALS Association, there are approximately 20,000 ALS patients in the U.S. and approximately 5,000 people in the U.S. are diagnosed with ALS each year. About MN-166 (ibudilast) MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor (MIF) inhibitor and phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. Our earlier human studies demonstrated significant reductions of serum MIF level after treatment with MN-166 (ibudilast). It also attenuates activated glial cells, which play a major role in certain neurological conditions. MN-166 (ibudilast)'s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical studies, which provide the rationale for treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS) and other neurological diseases such as glioblastoma (GBM), and substance abuse/addiction. MediciNova is developing MN-166 for ALS, progressive MS and other neurological conditions such as degenerative cervical myelopathy (DCM), glioblastoma, substance abuse/addiction, and chemotherapy-induced peripheral neuropathy, as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19. MediciNova has a portfolio of patents which covers the use of MN-166 (ibudilast) to treat various diseases including ALS, progressive MS, and drug addiction. About MediciNova MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on BC-PIV SARS-COV-2 vaccine for COVID-19, MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). For more information on MediciNova, Inc., please visit www.medicinova.com. Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements. INVESTOR CONTACT:Geoff O'BrienVice PresidentMediciNova, Inc.email@example.com
Bruce Howe DC, CCN releases ‘Body on Fire: 6 Proven Steps To Extinguish Inflammation’ SAN DIEGO, Jan. 18, 2021 (GLOBE NEWSWIRE) -- As a cancer survivor who has experienced the devastating effects of cancer, Dr. Bruce Howe made it his mission to research the subject of inflammation and the reason he has written “Body on Fire: 6 Proven Steps To Extinguish Inflammation” (published by Balboa Press) is a book that provides a simple solution to conquer inflammation, the underlying cause of the majority of the disease today. In the chapters ahead, readers will learn what inflammation is, the reason that it is an epidemic, its impact on health and its role in many diseases. Most importantly, they will learn how they can make lifestyle changes to extinguish the inflammatory fire. Readers also learn about real people who have successfully treated numerous health conditions by adopting the Extinguish the Flame Program strategies. These stories are based on Dr. Howe’s own patients and the patients of other health-care practitioners. “We are bombarded with quick fix solutions for health related disorders every day. There is a pill to treat nearly every disease. People are looking for ways to live healthier and longer without the side effects associated with the myriad of drugs. This book offers such a solution,” Howe says. When asked what he wants readers to take away from the book, Howe answers “Every small change a person can makes in the Extinguish the Flame Program can make a difference in not only how they feel today, but how long and how well they will live going forward.” For more details about the book, please visit https://www.balboapress.com/en/bookstore/bookdetails/810388-body-on-fire “Body on Fire: 6 Proven Steps To Extinguish Inflammation” By Bruce Howe DC, CCN Hardcover | 6 x 9in | 180 pages | ISBN 9781982255732 Softcover | 6x 9in | 180 pages | ISBN 9781982255718 E-Book | 180 pages | ISBN 9781982255725 Available at Amazon and Barnes & Noble About the Author Bruce Howe DC, CCN is a results oriented health care professional with over 38 years of demonstrated success encompassing private practice, research and product development, building and growing three highly successful businesses in nutrition, professional speaker, lecturer and author. He has undergraduate degree from the University of Minnesota and is a graduate of Northwestern University Health Science where he graduated with a doctorate degree in chiropractic. He is a Board Certified Clinical Nutritionist (CCN), and holds two nutritional patents and has two patent pending. He has been a consultant to numerous nutritional companies regarding formulations and product development. He is currently the owner and co-founder of Nutragen Health Innovations. Dr. Howe resides in Solana Beach, California with his wife and two sons. Balboa Press, a division of Hay House, Inc. – a leading provider in publishing products that specialize in self-help and the mind, body, and spirit genres. Through an alliance with the worldwide self-publishing leader Author Solutions, LLC, authors benefit from the leadership of Hay House Publishing and the speed-to-market advantages of the self-publishing model. For more information, visit balboapress.com. To start publishing your book with Balboa Press, call 844-682-1282 today. Attachment Cover_l CONTACT: Marketing Services Balboa Press 844-682-1282 firstname.lastname@example.org
A certain Big Bang Theory star is also trying her hand in hosting ...From Good Housekeeping